Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Triples Estimate On Deaths Following Allergic Reaction To Blood Thinner Heparin

This article was originally published in PharmAsia News

Executive Summary

BEIJING - U.S. FDA last week issued a sharply higher estimate on the number of deaths that have occurred in patients who suffered allergic reactions to the blood thinner heparin
Advertisement

Related Content

U.S. FDA Set To Strengthen Inspections Of Chinese Drugmakers, Search For Adulterants In Aftermath Of Heparin Deaths – CDER Official
FDA Set To Strengthen Inspections Of Chinese Drugmakers In Aftermath Of Heparin Deaths – CDER Official
China Emerging As Big Winner In Pharma Outsourcing Rush To Asia - PwC
China Emerging As Big Winner In Pharma Outsourcing Rush To Asia -- PwC
Shanghai FDA Signs Agreement With U.S. Law Firm To Foster International Cooperation on Drug Regulation
U.S. FDA Pinpoints Culprit In Bad Heparin
Foreign Drug Inspections Would Be Funded By Registration Fees In Draft U.S. Bill
Uncertainty About Supply Chain Keeps Baxter Out Of Heparin Market
U.S. FDA Counts 62 Deaths That Could Be Tied To Chinese Heparin
Baxter’s Chinese API Supplier Cited For “Objectionable Practices;” Remaining Heparin Vials Recalled
Advertisement
UsernamePublicRestriction

Register

SC068196

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel